Use of procalcitonin for the prediction and treatment of acute bacterial infection in children

Current Opinion in Pediatrics

Volumn 26, Issue 3, 2014, Pages 292-298

  Pierce, Richard ^a   Bigham, Michael T ^b   Giuliano, John S ^c  

^a YALE NEW HAVEN CHILDREN S HOSPITAL   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; biomarkers; pediatrics; sepsis

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROCALCITONIN; ANTIINFECTIVE AGENT; CALCITONIN; PROTEIN PRECURSOR;

ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CARDIOPULMONARY BYPASS; CHILDHOOD DISEASE; CONGENITAL HEART MALFORMATION; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEVER; HUMAN; NEUTROPENIA; NEWBORN SEPSIS; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SICKLE CELL ANEMIA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; BACTEREMIA; BACTERIAL INFECTIONS; BLOOD; CHILD; INFLAMMATION; PRESCHOOL CHILD; PROGNOSIS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CALCITONIN; CHILD; CHILD, PRESCHOOL; HUMANS; INFLAMMATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY;

EID: 84900450739     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000092     Document Type: Review

References (42)

1. Becker KL, Nylen ES, White JC, et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89: 1512-1525
2. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010; 159:253-264
3. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 2012; 73:221-227
4. Liappis AP, Gibbs KW, Nylen ES, et al. Exogenous procalcitonin evokes a proinflammatory cytokine response. Inflamm Res 2011; 60:203-207
5. Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin ampli fies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med 2002; 30:2091-2095
6. Wiedermann FJ, Kaneider N, Egger P, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med 2002; 30:1112-1117
7. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36:941-952
8. Auriti C, Fiscarelli E, Ronchetti MP, et al. Procalcitonin in detecting neonatal nosocomial sepsis. Arch Dis Child Fetal Neonatal Ed 2012; 97:F368-F370
9. Vouloumanou EK, Plessa E, Karageorgopoulos DE, et al. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and metaanalysis. Intensi ve Care Med 2011; 37:747-762
10. Gomez B, Bressan S, Mintegi S, et al. Diagnostic value of procalcitonin in well appearing young febrile infants. Pediatrics 2012; 130:815-822
11. Van den Bruel A, Thompson MJ, Haj-Hassan T, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. BMJ 2011; 342:d3082
12. Yo CH, Hsieh PS, Lee SH, et al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without s ource: a systematic review and meta-analysis. Ann Emerg Med 2012; 60:591-600
13. Bressan S, Gomez B, Mintegi S, et al. Diagnostic performance of the labscore in predicting severe and invasive b acterial infections in well appearing young febrile infants. Pediatr Infect Dis J 2012; 31:1239-1244
14. Leroy S, Fernandez-Lopez A, Nikfar R, et al. Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI. Pediatrics 2013; 131:870-879
15. Phil lips RS Wade R Lehrnbecher T et al. Systematic review and metaanalysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 2012; 10 6
16. Lin SG, Hou TY, Huang DH, et al. Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and neutropenia-A systemic review and meta-analysis. Pediatr Infec t Dis J 2012; 31:e182-e188
17. Mathew B, Roy DD, Kumar TV. The use of procalcitonin as a marker of sepsis in children. J Clin Diagn Res 2013; 7:305-307
18. Van Rossum AM, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 2004; 4:620-630
19. Nahum E, Schiller O, Livni G, et al. Procalcitonin level as an aid for the diagnosis of bacterial infections following pediatric cardiac surgery. J Crit Care 2012; 27:220.e11-220.e16
20. Garcia IJ, Gargallo MB, Torne EE, et al. Procalcitonin: a useful biomarker to discriminate infection after cardiopulmonary bypass in children. Pediatr Crit Care Med 2012; 13:441-445
21. Rungatscher A, Merlini A, De Rita F, et al. Diagnosis of infection in paediatric veno-arterial cardiac extracorporeal membrane oxygenation: role of procalcitonin and C-reactive protein. Eur J Cardiothorac Surg 2013; 43:1043-1049
22. Leroy S, Romane llo C, Galetto-Lacour A, et al. Procalcitonin is a predictor for high-grade vesicoureteral reflux in children: meta-analysis of individual patient data. J Pediatr 2011; 159:644.e4-651.e4
23. Unal S, Arslankoylu A, Kuyucu N, et al. Procalcitonin is more useful than C-reactive protein in fever in patients with sickle cell disease. J Pediatr Hematol Oncol 2012; 34:85-89
24. Bulloch AJK, Henr y B, Shah M, et al. Procalcitonin as a marker of bacteremia in children with fever and a central venous catheter presenting to the emergency department. Pediatr Emerg Care 2012; 28:1017-1021
25. De llinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2013; 41:580-637
26. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003
27. Tang BMP, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210-217
28. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13:426-435
29. Han YY, Doughty LA, Kofos D, et al. Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med 2003; 4:21-25
30. Arkader R, Tros ter EJ, Lopes MR, et al. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child 2006; 91:117-120
31. Rey C, Los Arcos M, Concha A, et al. Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med 2007; 33:477-484
32. Rey C, Garcia-Hernandez I, Concha A, et al. Pro-adrenomedullin, proendothelin 1, procalcitonin, C-reactive protein and mortality risk in critically ill children. Crit Care 2013; 17:R240. [Epub ahead of print]
33. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9:CD007498
34. Christ-Crain M, Jacca rd-Stolz D, Bingisser R, et al. Effect of procalcitoninguided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607
35. Oliveira CF, Botoni FA, Oliveira CR, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 2013; 41:2336-2343
36. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011; 39:179 2-1799
37. Prkno A Wacker C Brunkhorst FM Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock-A systematic review and meta-analysis. Crit Care 2013 17 R291
38. Assink-de Jong E, de Lange DW, van Oers JA, et al. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomized prospective multicenter investigator-initiated trial to analyse w hether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients-calculated sample size: 1816 patients. BMC Infect Dis 2013; 13
39. Esposito S, Tagliabue C, Picciolli I, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med 2011; 105: 1939-1945
40. Baer G, Bau mann P, Buettcher M, et al. Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial. PLoS One 2013; 8: e68419
41. Cohen JF, Leis A, Lecarpentier T, et al. Procalcitonin predicts response to beta-lactam treatment in hospitalized children with community-acquired pneumonia. PLoS One 2012; 7:e36927
42. Stocker M, Fontana M, El Helou S, et al. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 2010; 97:165-174.